

What is claimed is:

1. A method of treating prostate cancer in a human comprising administering to the human a therapeutically effective amount of an antibody which binds ErbB2 and blocks ligand activation of an ErbB receptor.
2. The method of claim 1 wherein the antibody blocks binding of monoclonal antibody 2C4 to ErbB2.
3. The method of claim 1 wherein the antibody blocks TGF- α activation of mitogen-activated protein kinase (MAPK).
4. The method of claim 1 wherein the antibody has a biological characteristic of monoclonal antibody 2C4.
5. The method of claim 4 wherein the antibody comprises monoclonal antibody 2C4 or humanized 2C4.
6. The method of claim 1 wherein the antibody is an antibody fragment.
7. The method of claim 6 wherein the antibody fragment is a Fab fragment.
8. The method of claim 1 wherein the antibody is not conjugated with a cytotoxic agent.
9. The method of claim 6 wherein the antibody fragment is not conjugated with a cytotoxic agent.
10. The method of claim 1 wherein the antibody is conjugated with a cytotoxic agent.
11. A method of treating prostate cancer in a human comprising administering to the human therapeutically effective amounts of a chemotherapeutic agent and of an antibody which binds ErbB2 and blocks ligand activation of an ErbB receptor.
12. The method of claim 11 wherein the chemotherapeutic agent is a taxane.
13. An article of manufacture comprising a container and a composition contained therein, wherein the composition comprises an antibody which binds ErbB2 and blocks ligand activation of an ErbB receptor, and further comprising a package insert indicating that the composition can be used to treat prostate cancer.
14. The article of manufacture of claim 13 wherein the package insert further indicates treating the patient with a chemotherapeutic agent.
15. The article of manufacture of claim 13 wherein the chemotherapeutic agent is a taxane.

- nd
A4